{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Other+Tumors&page=2", "query": { "condition": "Other Tumors", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Other+Tumors&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T22:28:31.320Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06160752", "title": "Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Cholangiocarcinoma", "Intrahepatic Cholangiocarcinoma", "Solid Tumor", "Metastatic Cholangiocarcinoma" ], "interventions": [ { "name": "Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles", "type": "DRUG" }, { "name": "Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyra Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2023-11-22", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2024-10-03", "last_synced_at": "2026-07-23T22:28:31.320Z", "location_count": 4, "location_summary": "San Francisco, California • Boston, Massachusetts • Columbus, Ohio + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06160752" }, { "nct_id": "NCT07620548", "title": "Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Glioblastoma, IDH-wildtype", "Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype" ], "interventions": [ { "name": "NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy", "type": "DEVICE" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2026-08-31", "completion_date": "2032-08-31", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-07-23T22:28:31.320Z", "location_count": 2, "location_summary": "Rochester, Minnesota • St Louis, Missouri", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07620548" }, { "nct_id": "NCT01980732", "title": "68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Carcinoid Tumors", "Islet Cell (Pancreatic NET)", "Other Neuroendocrine Tumors" ], "interventions": [ { "name": "68Ga-DOTA TATE", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Andrei Iagaru", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2017-08-23", "last_synced_at": "2026-07-23T22:28:31.320Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01980732" }, { "nct_id": "NCT04276597", "title": "Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Neuroendocrine Neoplasm", "Pheochromocytoma", "Paraganglioma", "Thymus Carcinoid", "Unknown Primary Tumors", "Neuroendocrine Tumors", "Neuroendocrine Skin Carcinoma", "Neuroendocrine Breast Tumor", "Neuroendocrine Carcinoma Metastatic", "Neuroendocrine Neoplasm of Ovary" ], "interventions": [ { "name": "177Lu-DOTATOC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Excel Diagnostics and Nuclear Oncology Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-03-04", "completion_date": "2021-07-15", "has_results": false, "last_update_posted_date": "2023-03-10", "last_synced_at": "2026-07-23T22:28:31.320Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04276597" }, { "nct_id": "NCT04853017", "title": "A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Minimal Residual Disease", "KRAS G12D", "KRAS G12R", "NRAS G12D", "NRAS G12R", "Pancreatic Ductal Adenocarcinoma", "Colorectal Cancer", "Non-small Cell Lung Cancer", "Ovarian Cancer", "Cholangiocarcinoma", "Bile Duct Cancer", "Gallbladder Carcinoma" ], "interventions": [ { "name": "ELI-002 2P", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elicio Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-10-04", "completion_date": "2024-09-24", "has_results": true, "last_update_posted_date": "2025-09-05", "last_synced_at": "2026-07-23T22:28:31.320Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04853017" }, { "nct_id": "NCT03864042", "title": "Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Metastatic Melanoma" ], "interventions": [ { "name": "losartan", "type": "DRUG" }, { "name": "dextromethorphan", "type": "DRUG" }, { "name": "caffeine", "type": "DRUG" }, { "name": "omeprazole", "type": "DRUG" }, { "name": "midazolam", "type": "DRUG" }, { "name": "rosuvastatin", "type": "DRUG" }, { "name": "bupropion immediate release (IR)", "type": "DRUG" }, { "name": "encorafenib", "type": "DRUG" }, { "name": "binimetinib", "type": "DRUG" }, { "name": "modafinil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2018-01-02", "completion_date": "2023-05-29", "has_results": true, "last_update_posted_date": "2024-09-27", "last_synced_at": "2026-07-23T22:28:31.320Z", "location_count": 11, "location_summary": "Orange, California • Aurora, Colorado • Chicago, Illinois + 7 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Hopkins", "state": "Minnesota" }, { "city": "Maple Grove", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03864042" }, { "nct_id": "NCT02560883", "title": "Hairy Cell Leukemia Patient Data Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Leukemia, Other" ], "interventions": [], "intervention_types": [], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5000, "start_date": "2013-01-02", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-07-23T22:28:31.320Z", "location_count": 5, "location_summary": "Miami, Florida • Miami Beach, Florida • Rochester, Minnesota + 2 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Rochester", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02560883" }, { "nct_id": "NCT04883775", "title": "Study of a New Technique for Imaging Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Tumors That Express CA19-9" ], "interventions": [ { "name": "MVT-2163", "type": "DRUG" }, { "name": "MVT-5873", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2021-05-10", "completion_date": "2025-01-27", "has_results": false, "last_update_posted_date": "2025-01-30", "last_synced_at": "2026-07-23T22:28:31.320Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04883775" }, { "nct_id": "NCT02554812", "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Utomilumab", "type": "DRUG" }, { "name": "PF-04518600", "type": "DRUG" }, { "name": "PD 0360324", "type": "DRUG" }, { "name": "CMP-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 409, "start_date": "2015-11-09", "completion_date": "2023-03-23", "has_results": true, "last_update_posted_date": "2024-07-30", "last_synced_at": "2026-07-23T22:28:31.320Z", "location_count": 57, "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 23 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02554812" }, { "nct_id": "NCT01640522", "title": "Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hepatocellular Carcinoma", "Primary Liver Cancer", "Bile Duct Cancer", "Pancreatic Cancer", "Gallbladder Cancer", "Colorectal Carcinoma", "Liver Metastases" ], "interventions": [ { "name": "Collaborative Care", "type": "OTHER" }, { "name": "Enhanced usual Care", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 261, "start_date": "2008-01", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2024-12-13", "last_synced_at": "2026-07-23T22:28:31.320Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01640522" } ] }